Dipeptidyl peptidase-4 (DPP-4) inhibitors have been broadly used to treat T2DM via elevating endogenous GLP-1 level and inhibiting gastric emptying (Pratley and Salsali, 2007). The gene discussed is DPP4; the disease is type 2 diabetes mellitus.